23 April 2024 - Roche Canada will be working closely with the pan-Canadian Pharmaceutical Alliance, as well as federal, provincial, and territorial agencies in Canada to ensure patients can access Tecentriq SC as quickly as possible.

Roche Canada is pleased to announce that on 13 March  2024, Health Canada issued marketing authorisation for Tecentriq SC (atezolizumab solution for subcutaneous injection), the first cancer immunotherapy for subcutaneous administration in Canada, for specific indications in lung cancer, hepatocellular carcinoma, and breast cancer.

Read Roche press release